<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382963</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1550</org_study_id>
    <secondary_id>A535700</secondary_id>
    <secondary_id>SMPH/NEURO SURG/NEURO SURG</secondary_id>
    <secondary_id>Protocol Version 11/12/2020</secondary_id>
    <nct_id>NCT04382963</nct_id>
  </id_info>
  <brief_title>Stroke Prevention in the Wisconsin Native American Population</brief_title>
  <official_title>Stroke Prevention in the Wisconsin Native American Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wisconsin Partnership Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will develop a &quot;Stroke Awareness Team&quot; including training of Oneida Health&#xD;
      Service Coaches working in partnership with the UW team for a population-based health&#xD;
      awareness program. This team will develop a series of Oneida Nation Healthy Living and Stroke&#xD;
      Awareness Events (from now on health events) to provide education as to the severity of the&#xD;
      problem as well as our standard therapies for lifestyle change and risk factor avoidance.&#xD;
      This will include education of the healthy members of the tribe including the children to&#xD;
      identify signs of stroke and TIA in their elders as well as to develop healthy lifestyles at&#xD;
      the earliest of ages to influence the elders to modify their risks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 100 high risk tribe members and 20 low stroke risk tribe members. Each&#xD;
      of these will be further studied for their atherosclerotic load by ultrasound measurements at&#xD;
      the carotid bifurcation for presence of plaque as well as its stability or instability during&#xD;
      pulsation. Enrolled participants will also receive assessment of biomarkers for stroke risk,&#xD;
      including stroke-related vascular cognitive decline, an early and modifiable marker of TIA&#xD;
      risk and serum analysis for glucose, cholesterol, microRNA and key proteins felt to be&#xD;
      biomarkers of stroke.&#xD;
&#xD;
      The high risk participants will be divided into two groups, stratified by gender, age,&#xD;
      history of cerebrovascular events, and the presence or absence of atherosclerosis in their&#xD;
      carotid bifurcation including equal numbers of participants that in spite of high risk, have&#xD;
      not yet deposited plaque.&#xD;
&#xD;
        -  One group will receive advice about standard therapy and information concerning risk&#xD;
           factor guidelines to improve health awareness.&#xD;
&#xD;
        -  The other group will receive the same plus intensive initiation of the American Heart&#xD;
           Association Guidelines for Management of Risk Factors with at least quarterly individual&#xD;
           face-to-face coaching meetings on lifestyle change and adherence to treatment.&#xD;
&#xD;
      At the end of 2-year follow-up, all groups will be reassessed for adherence to the program,&#xD;
      atherosclerotic plaque progression or regression and its stability, serum biomarker response&#xD;
      to therapy interventions, successful risk factor modification, vascular cognitive decline and&#xD;
      incidence of stroke and TIA. Intention to treat analysis will estimate the efficacy of health&#xD;
      coaching and will use G-estimation to correct for issues of non-compliance and&#xD;
      discontinuation. Groups will be compared for change in both risk factors and outcomes.&#xD;
&#xD;
      Vascular cognitive decline is an important symptom of cerebrovascular disease which may&#xD;
      precede a physical stroke with devastating results. Extensive preliminary data show that the&#xD;
      frequency of this is surprisingly common in high risk patients and may predispose patients to&#xD;
      later dementia. Vascular cognitive decline is a risk factor for stroke, but also is&#xD;
      modifiable. A prior small study showed that intervention could stop the rate of decline. The&#xD;
      study will see if this predicts participants at greatest risk for stroke that would improve&#xD;
      with an intensive intervention program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Incidence of Stroke or TIA</measure>
    <time_frame>baseline and 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Diastolic Blood Pressure</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Number of Participants with diastolic blood pressure &lt; 90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Systolic Blood Pressure</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Number of Participants with systolic blood pressure &lt; 140 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Total Cholesterol</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Number of Participants with total cholesterol &lt; 200 mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Number of Participants with LDL-C &lt; 100 mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Number of Participants with HDL-C &gt; 60 mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Blood Sugar</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Number of Participants with A1c &lt; 7.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Body Mass Index (BMI)</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Number of Participants who improve BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Participants that meet AHA Simple Rules for Smoking Status</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Number of Participants who Smoke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CERAD-NAB Score</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>The Consortium to Establish a Registry for Alzheimer's disease-Neuropsychological Assessment Battery (CERAD-NAB) is a cognitive assessment of episodic memory by asking the participant to recall 10 unrelated words before and after a 5-10 minute delay. Scores are from 0 to 10 depending on the words recalled. Interpretation of scoring is encoded relative to education and age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plaque Area</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Measured via carotid ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulsatile Strain in Arterial Plaque</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Measured via carotid ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Grayscale Median (GSM) Values</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Measured via carotid ultrasound. [Is this a measure of size?]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Dipeptidyl Peptidase (DPPIV)</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>DPPIV is a circulating protein associated with cardiovascular risk. This will be measured via blood draw at baseline and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Galectin3 (Gal-3)</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Gal-3 is a circulating protein associated with cardiovascular risk. This will be measured via blood draw at baseline and 2 years.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Serum microRNA</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>Levels of serum microRNA are associated with increased stroke risk. This will be measured via blood draw at baseline and 2 years.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance Rates</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stroke</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>High Risk- intense coaching</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>age ≥ 55 with MORE than three of the following risk factors:&#xD;
History of TIA/Stroke&#xD;
History of Coronary Artery disease&#xD;
History of Hypertension and/or current elevated blood pressure&#xD;
History of Diabetes&#xD;
Current smoker&#xD;
BMI ≥30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk - standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>age ≥ 55 with MORE than three of the following risk factors:&#xD;
History of TIA/Stroke&#xD;
History of Coronary Artery disease&#xD;
History of Hypertension and/or current elevated blood pressure&#xD;
History of Diabetes&#xD;
Current smoker&#xD;
BMI ≥30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk - control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>age ≥ 55 with LESS than three of the following risk factors:&#xD;
History of TIA/Stroke&#xD;
History of Coronary Artery disease&#xD;
History of Hypertension and/or current elevated blood pressure&#xD;
History of Diabetes&#xD;
Current smoker&#xD;
BMI ≥30</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Risk - intensive coaching</intervention_name>
    <description>The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.&#xD;
Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis.</description>
    <arm_group_label>High Risk- intense coaching</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Risk - standard care</intervention_name>
    <description>The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.</description>
    <arm_group_label>High Risk - standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Risk - control</intervention_name>
    <description>Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.</description>
    <arm_group_label>Low risk - control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants receiving health care through the Oneida Health Council Program&#xD;
&#xD;
          -  Participants deemed to be at high risk for stroke by modified Framingham assessment of&#xD;
             medical history, including cerebral cardiovascular symptomatology, hypertension,&#xD;
             diabetes, smoking, BMI&#xD;
&#xD;
          -  Willingness to participate in the study, including two-year follow-up&#xD;
&#xD;
          -  Controls will be selected using the same criteria with the exception that upon&#xD;
             screening, they are not deemed to be at high risk for stroke.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of established dementia&#xD;
&#xD;
          -  Inability to participate in physical and exercise programs due to preexisting&#xD;
             disability&#xD;
&#xD;
          -  Illiteracy&#xD;
&#xD;
          -  Prior carotid procedure altering ultrasound finding&#xD;
&#xD;
          -  Presence of medical condition precluding participation or follow-up over a two-year&#xD;
             period of time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Dempsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Wilbrand, PhD</last_name>
    <phone>608-265-9248</phone>
    <email>wilbrand@neurosurgery.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Mitchell, PhD</last_name>
    <phone>608-262-0680</phone>
    <email>ccm@medicine.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Dempsety, MD</last_name>
      <phone>608-265-5967</phone>
      <email>dempsey@neurosurgery.wisc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oneida Comprehensive Health Division</name>
      <address>
        <city>Oneida</city>
        <state>Wisconsin</state>
        <zip>54155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravinder Vir, MD</last_name>
      <phone>920-869-4808</phone>
      <email>rvir@oneidanation.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Harris R, Nelson LA, Muller C, Buchwald D. Stroke in American Indians and Alaska Natives: A Systematic Review. Am J Public Health. 2015 Aug;105(8):e16-26. doi: 10.2105/AJPH.2015.302698. Epub 2015 Jun 11. Review.</citation>
    <PMID>26066955</PMID>
  </reference>
  <reference>
    <citation>Berman SE, Wang X, Mitchell CC, Kundu B, Jackson DC, Wilbrand SM, Varghese T, Hermann BP, Rowley HA, Johnson SC, Dempsey RJ. The relationship between carotid artery plaque stability and white matter ischemic injury. Neuroimage Clin. 2015 Aug 22;9:216-22. doi: 10.1016/j.nicl.2015.08.011. eCollection 2015.</citation>
    <PMID>26448914</PMID>
  </reference>
  <reference>
    <citation>Darwish MA, Hammon WM. Studies on Japanese B encephalitis virus vaccines from tissue culture. VI. Development of a hamster kidney tissue culture inactivated vaccine for man. 3. Potency testing of an attenuated strain of OCT-541. J Immunol. 1966 May;96(5):878-84.</citation>
    <PMID>4288023</PMID>
  </reference>
  <reference>
    <citation>Wesley UV, Hatcher JF, Ayvaci ER, Klemp A, Dempsey RJ. Regulation of Dipeptidyl Peptidase IV in the Post-stroke Rat Brain and In Vitro Ischemia: Implications for Chemokine-Mediated Neural Progenitor Cell Migration and Angiogenesis. Mol Neurobiol. 2017 Sep;54(7):4973-4985. doi: 10.1007/s12035-016-0039-4. Epub 2016 Aug 15.</citation>
    <PMID>27525674</PMID>
  </reference>
  <reference>
    <citation>Amersfoort J, Schaftenaar FH, Douna H, van Santbrink PJ, Kröner MJ, van Puijvelde GHM, Quax PHA, Kuiper J, Bot I. Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner. Atherosclerosis. 2018 Aug;275:214-224. doi: 10.1016/j.atherosclerosis.2018.06.015. Epub 2018 Jun 13.</citation>
    <PMID>29960897</PMID>
  </reference>
  <reference>
    <citation>Hochmeister S, Engel O, Adzemovic MZ, Pekar T, Kendlbacher P, Zeitelhofer M, Haindl M, Meisel A, Fazekas F, Seifert-Held T. Lipocalin-2 as an Infection-Related Biomarker to Predict Clinical Outcome in Ischemic Stroke. PLoS One. 2016 May 6;11(5):e0154797. doi: 10.1371/journal.pone.0154797. eCollection 2016.</citation>
    <PMID>27152948</PMID>
  </reference>
  <reference>
    <citation>Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clin Trials. 2008;5(1):5-13. doi: 10.1177/1740774507087703.</citation>
    <PMID>18283074</PMID>
  </reference>
  <reference>
    <citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003 Mar 27;348(13):1215-22.</citation>
    <PMID>12660385</PMID>
  </reference>
  <reference>
    <citation>Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol. 2007 Jun 1;165(11):1231-8. Epub 2007 Apr 12.</citation>
    <PMID>17431012</PMID>
  </reference>
  <reference>
    <citation>Mitchell CC, Stein JH, Cook TD, Salamat S, Wang X, Varghese T, Jackson DC, Sandoval Garcia C, Wilbrand SM, Dempsey RJ. Histopathologic Validation of Grayscale Carotid Plaque Characteristics Related to Plaque Vulnerability. Ultrasound Med Biol. 2017 Jan;43(1):129-137. doi: 10.1016/j.ultrasmedbio.2016.08.011. Epub 2016 Oct 5.</citation>
    <PMID>27720278</PMID>
  </reference>
  <reference>
    <citation>Jackson DC, Sandoval-Garcia C, Rocque BG, Wilbrand SM, Mitchell CC, Hermann BP, Dempsey RJ. Cognitive Deficits in Symptomatic and Asymptomatic Carotid Endarterectomy Surgical Candidates. Arch Clin Neuropsychol. 2016 Feb;31(1):1-7. doi: 10.1093/arclin/acv082. Epub 2015 Dec 10.</citation>
    <PMID>26663810</PMID>
  </reference>
  <reference>
    <citation>Dempsey RJ, Jackson DC, Wilbrand SM, Mitchell CC, Berman SE, Johnson SC, Meshram NH, Varghese T, Hermann BP. The Preservation of Cognition 1 Year After Carotid Endarterectomy in Patients With Prior Cognitive Decline. Neurosurgery. 2018 Mar 1;82(3):322-328. doi: 10.1093/neuros/nyx173.</citation>
    <PMID>28575478</PMID>
  </reference>
  <reference>
    <citation>Dempsey RJ, Varghese T, Jackson DC, Wang X, Meshram NH, Mitchell CC, Hermann BP, Johnson SC, Berman SE, Wilbrand SM. Carotid atherosclerotic plaque instability and cognition determined by ultrasound-measured plaque strain in asymptomatic patients with significant stenosis. J Neurosurg. 2018 Jan;128(1):111-119. doi: 10.3171/2016.10.JNS161299. Epub 2017 Mar 10.</citation>
    <PMID>28298048</PMID>
  </reference>
  <reference>
    <citation>Mitchell CC, Wilbrand SM, Kundu B, Steffel CN, Varghese T, Meshram NH, Li G, Cook TD, Salamat MS, Dempsey RJ. Transcranial Doppler and Microemboli Detection: Relationships to Symptomatic Status and Histopathology Findings. Ultrasound Med Biol. 2017 Sep;43(9):1861-1867. doi: 10.1016/j.ultrasmedbio.2017.04.025. Epub 2017 Jun 20.</citation>
    <PMID>28645797</PMID>
  </reference>
  <reference>
    <citation>Wang X, Jackson DC, Mitchell CC, Varghese T, Wilbrand SM, Rocque BG, Hermann BP, Dempsey RJ. Classification of Symptomatic and Asymptomatic Patients with and without Cognitive Decline Using Non-invasive Carotid Plaque Strain Indices as Biomarkers. Ultrasound Med Biol. 2016 Apr;42(4):909-18. doi: 10.1016/j.ultrasmedbio.2015.11.025. Epub 2016 Jan 5.</citation>
    <PMID>26778288</PMID>
  </reference>
  <reference>
    <citation>Wang X, Jackson DC, Varghese T, Mitchell CC, Hermann BP, Kliewer MA, Dempsey RJ. Correlation of cognitive function with ultrasound strain indices in carotid plaque. Ultrasound Med Biol. 2014 Jan;40(1):78-89. doi: 10.1016/j.ultrasmedbio.2013.08.001. Epub 2013 Oct 11.</citation>
    <PMID>24120415</PMID>
  </reference>
  <reference>
    <citation>Rocque BG, Jackson D, Varghese T, Hermann B, McCormick M, Kliewer M, Mitchell C, Dempsey RJ. Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements. J Neurol Sci. 2012 Nov 15;322(1-2):20-4. doi: 10.1016/j.jns.2012.05.020. Epub 2012 Jun 1.</citation>
    <PMID>22658531</PMID>
  </reference>
  <reference>
    <citation>McCormick M, Varghese T, Wang X, Mitchell C, Kliewer MA, Dempsey RJ. Methods for robust in vivo strain estimation in the carotid artery. Phys Med Biol. 2012 Nov 21;57(22):7329-53. doi: 10.1088/0031-9155/57/22/7329. Epub 2012 Oct 18.</citation>
    <PMID>23079725</PMID>
  </reference>
  <reference>
    <citation>Dempsey RJ, Vemuganti R, Varghese T, Hermann BP. A review of carotid atherosclerosis and vascular cognitive decline: a new understanding of the keys to symptomology. Neurosurgery. 2010 Aug;67(2):484-93; discussion 493-4. doi: 10.1227/01.NEU.0000371730.11404.36. Review.</citation>
    <PMID>20644437</PMID>
  </reference>
  <reference>
    <citation>Shi H, Varghese T, Dempsey RJ, Salamat MS, Zagzebski JA. Relationship between ultrasonic attenuation, size and axial strain parameters for ex vivo atherosclerotic carotid plaque. Ultrasound Med Biol. 2008 Oct;34(10):1666-77. doi: 10.1016/j.ultrasmedbio.2008.02.014. Epub 2008 May 19.</citation>
    <PMID>18490099</PMID>
  </reference>
  <reference>
    <citation>Wang X, Mitchell CC, Varghese T, Jackson DC, Rocque BG, Hermann BP, Dempsey RJ. Improved Correlation of Strain Indices with Cognitive Dysfunction with Inclusion of Adventitial Layer with Carotid Plaque. Ultrason Imaging. 2016 May;38(3):194-208. doi: 10.1177/0161734615589252. Epub 2015 May 28.</citation>
    <PMID>26025578</PMID>
  </reference>
  <reference>
    <citation>Meshram NH, Varghese T, Mitchell CC, Jackson DC, Wilbrand SM, Hermann BP, Dempsey RJ. Quantification of carotid artery plaque stability with multiple region of interest based ultrasound strain indices and relationship with cognition. Phys Med Biol. 2017 Jul 17;62(15):6341-6360. doi: 10.1088/1361-6560/aa781f.</citation>
    <PMID>28594333</PMID>
  </reference>
  <reference>
    <citation>Barnett PA, Spence JD, Manuck SB, Jennings JR. Psychological stress and the progression of carotid artery disease. J Hypertens. 1997 Jan;15(1):49-55.</citation>
    <PMID>9050970</PMID>
  </reference>
  <reference>
    <citation>Pavlović-Hournac M, Delbauffe D. Protein metabolism in hypo- and hyperstimulated rat thyroid glands. II. Degradation of newly formed thyroidal proteins. Horm Metab Res. 1976 Jan;8(1):55-61.</citation>
    <PMID>1248791</PMID>
  </reference>
  <reference>
    <citation>Nicolaides AN, Kakkos SK, Kyriacou E, Griffin M, Sabetai M, Thomas DJ, Tegos T, Geroulakos G, Labropoulos N, Doré CJ, Morris TP, Naylor R, Abbott AL; Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. J Vasc Surg. 2010 Dec;52(6):1486-1496.e1-5. doi: 10.1016/j.jvs.2010.07.021.</citation>
    <PMID>21146746</PMID>
  </reference>
  <reference>
    <citation>Sztajzel R, Momjian S, Momjian-Mayor I, Murith N, Djebaili K, Boissard G, Comelli M, Pizolatto G. Stratified gray-scale median analysis and color mapping of the carotid plaque: correlation with endarterectomy specimen histology of 28 patients. Stroke. 2005 Apr;36(4):741-5. Epub 2005 Feb 10.</citation>
    <PMID>15705933</PMID>
  </reference>
  <reference>
    <citation>Mitchell CC, Korcarz CE, Tattersall MC, Gepner AD, Young RL, Post WS, Kaufman JD, McClelland RL, Stein JH. Carotid artery ultrasound texture, cardiovascular risk factors, and subclinical arterial disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Br J Radiol. 2018 Apr;91(1084):20170637. doi: 10.1259/bjr.20170637. Epub 2018 Jan 31.</citation>
    <PMID>29308915</PMID>
  </reference>
  <reference>
    <citation>Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994 Apr;44(4):609-14.</citation>
    <PMID>8164812</PMID>
  </reference>
  <reference>
    <citation>Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, Tariot PN, Silverman JM, Clark CM, Welsh-Bohmer KA, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement. 2008 Mar;4(2):96-109. doi: 10.1016/j.jalz.2007.08.005.</citation>
    <PMID>18631955</PMID>
  </reference>
  <reference>
    <citation>Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1998 Jul;51(1):159-62. Erratum in: Neurology 1998 Dec;51(6):1809.</citation>
    <PMID>9674796</PMID>
  </reference>
  <reference>
    <citation>Welsh KA, Fillenbaum G, Wilkinson W, Heyman A, Mohs RC, Stern Y, Harrell L, Edland SD, Beekly D. Neuropsychological test performance in African-American and white patients with Alzheimer's disease. Neurology. 1995 Dec;45(12):2207-11.</citation>
    <PMID>8848195</PMID>
  </reference>
  <reference>
    <citation>Fillenbaum GG, Burchett BM, Unverzagt FW, Rexroth DF, Welsh-Bohmer K. Norms for CERAD constructional praxis recall. Clin Neuropsychol. 2011 Nov;25(8):1345-58. doi: 10.1080/13854046.2011.614962. Epub 2011 Oct 13.</citation>
    <PMID>21992077</PMID>
  </reference>
  <reference>
    <citation>Whyte SR, Cullum CM, Hynan LS, Lacritz LH, Rosenberg RN, Weiner MF. Performance of elderly Native Americans and Caucasians on the CERAD Neuropsychological Battery. Alzheimer Dis Assoc Disord. 2005 Apr-Jun;19(2):74-8.</citation>
    <PMID>15942324</PMID>
  </reference>
  <reference>
    <citation>Ellis G, Rodger J, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. Age Ageing. 2005 Jul;34(4):389-92.</citation>
    <PMID>15955759</PMID>
  </reference>
  <reference>
    <citation>Vemuganti R. All's well that transcribes well: non-coding RNAs and post-stroke brain damage. Neurochem Int. 2013 Nov;63(5):438-49. doi: 10.1016/j.neuint.2013.07.014. Epub 2013 Aug 15. Review.</citation>
    <PMID>23954844</PMID>
  </reference>
  <reference>
    <citation>Vorlícek J, Mechl Z. [Nephrologic complications of oncologic therapy]. Cas Lek Cesk. 1985 Dec 13;124(50):1561-2. Czech.</citation>
    <PMID>4084961</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Native American</keyword>
  <keyword>Risk factor modification</keyword>
  <keyword>Proteonomics</keyword>
  <keyword>Genomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Following transparency and reproducibility guidelines (NIH NOT-OD-15-103), the data resulting from this research proposal will be made publicly available. This will help ensure that other researchers are able to reproduce and/or extend our findings, and will enhance the scientific rigor of this proposal. Data will be made available for download to any individual or organization who requests data and abides by a data-sharing agreement that will be developed. This agreement will require that the data be used solely for research, that individuals or organizations secure the data using conventional electronic safeguards, and that once data analysis is complete, the data be destroyed. In general, data acquired in this study will be made available publicly after initial key manuscripts have been accepted for publication. Manuscripts will include relevant methodological details to allow for reproducibility by other researchers and the ability to extend or findings.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

